Wedbush Reiterates Outperform Rating for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX)‘s stock had its “outperform” rating reiterated by Wedbush in a research report issued on Monday, Marketbeat Ratings reports. They presently have a $6.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research note on Monday, November 11th. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st.

Chimerix Stock Performance

Chimerix stock opened at $0.88 on Monday. The firm has a market cap of $79.15 million, a PE ratio of -0.94 and a beta of 1.13. The firm’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $0.91. Chimerix has a twelve month low of $0.75 and a twelve month high of $1.30.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Valeo Financial Advisors LLC increased its stake in shares of Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 69,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 138,098 shares during the last quarter. Marshall Wace LLP acquired a new position in Chimerix in the 2nd quarter valued at $137,000. Finally, Acadian Asset Management LLC grew its stake in Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 291,981 shares during the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.